Mar. 13 at 6:00 AM
$ADIL The company signed a major collaboration framework with Molteni Farmaceutici for the European commercialization of AD04 (their lead drug for Alcohol Use Disorder). The deal could be worth nearly
$60 million in milestones and royalties.
$SOS On February 17, 2026, SOS announced the launch of SosBOT 1.0, an AI-driven trading bot.